A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
NCT00435669
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
4
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Interventions
DRUG:
Brivanib
DRUG:
Brivanib
Sponsor
Bristol-Myers Squibb